Providence Swedish in the South Puget Sound region of Washington state will close a majority of its outpatient physical, occupational, and speech therapy programs, according to a news release shared with Becker’s.
Category: Channels
Optometrist to pay $1M+ to settle false claims allegations
An optometrist in Austin, Texas, has agreed to pay the U.S. and the state of Texas $1,055,379 to resolve allegations that he violated the False Claims Act and the Texas Health Care Program Fraud Prevention Act.
9 states targeting private equity
Private equity activity in healthcare has increased over the last decade, and some states have passed or have pending legislation that could increase scrutiny over private equity deals in healthcare.
Physician sues Kaiser Permanente-affiliated group for $8M
A Salem, Ore., radiologist has filed a lawsuit against a Kaiser Permanente-affiliated physician group alleging he faced retaliation after bringing forth fraud allegations against two other physicians, The Lund Report reported Nov. 1.
Cardiologist compensation, workforce in 2024: 10 notes
Here are 10 notes on the state of cardiology’s workforce and compensation in 2024, as reported by Becker’s:
50% of US drug shortages last at least 2 years: ASHP
A survey by the American Society of Health-System Pharmacists found that 50% of active drug shortages in the U.S. persist for two or more years, the Pharmacy Times reported Nov. 1.
50% of US drug shortages last at least 2 years: ASHP
A survey by the American Society of Health-System Pharmacists found that 50% of active drug shortages in the U.S. persist for two or more years, the Pharmacy Times reported Nov. 1.
State flags Connecticut hospital for service cuts: 9 notes
Connecticut’s Office of Health Strategy has raised concerns with Vernon, Conn.-based Rockville General Hospital’s service cuts that “may be in violation” of state law, according to an Oct. 17 letter.
Prime Healthcare Texas hospital taps CEO
Josiah De La Garza has been named CEO of Dallas Regional Medical Center in Mesquite, Texas.
Semaglutide shows improvement in liver disease treatment in late stage trial
A Novo Nordisk Phase 3 trial found that 37% of adults with metabolic dysfunction-associated steatohepatitis who received once-weekly semaglutide 2.4 milligrams showed improvement in liver fibrosis without worsening steatohepatitis, a disease that cause…
